ArticleNature2018
LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 190 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
190citing papers in PubMed, 1 pooled it
8.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
190 citing papers in PubMed, 1 synthesis or guideline pooled it, 290 citations in OpenAlex.
- In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways.Frontiers in immunology · 2022Pooled it
- Transcriptome Analysis Identifies a Myeloid-Like Signature in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy.Cancer medicine · 2026Trial
- A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.Blood neoplasia · 2025Trial
- Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients.Blood cancer journal · 2022Trial
- Cellular senescence: six decades of discovery and reinvention.The EMBO journal · 2026Review
- LILRB4 Recruits SHP-1 to Enhance Oxidative Stress and Apoptosis, Aggravating Myocardial Ischemia-Reperfusion Injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Cardiovascular-Kidney-Metabolic Syndrome Staging and Cancer Risk: Insights From Proteomic and Metabolomic Mediators.JACC. CardioOncology · 2026Article
- Generative AI-drivenAntibody therapeutics · 2026Article
- The search for safe and effective CAR-T targets in AML.Blood cancer journal · 2026Review
- Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed/refractory acute myeloid leukemia.Signal transduction and targeted therapy · 2026Article
- T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges.Cell reports. Medicine · 2026Review
- Spatiotemporal Transcriptomics Characterizes Immune Microenvironment During Mouse Liver Aging.Aging cell · 2026Article
- Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer.Science immunology · 2026Article
- LILRB4 shapes an immunosuppressive microenvironment to drive cervical cancer progression through tumor-infiltrating myeloid cell expansion and CD8Cellular and molecular life sciences : CMLS · 2026Article
- Homoharringtonine Promotes FTO Degradation to Suppress LILRB4-Mediated Immune Evasion in Acute Monocytic Leukaemia.Cell proliferation · 2026Article
- Review
- Tumor-associated macrophages educated by IGSF9 exhibit a senescence-associated secretory phenotype to promote tumor immune escape.Journal for immunotherapy of cancer · 2026Article
- The structure and functions of TRAF families and recent advances of TRAFs in leukemia.Frontiers in oncology · 2026Review
- Monocytic Cell Variations in Postallotransplant Environment: Balancing Graft Versus Host Disease and Graft-Versus-Leukemia Effect.Journal of immunology research · 2026Review
- Monocyte-Macrophage Lineages in Cancer: Biology, Plasticity, and Therapeutic Targeting.Cancer biome and targeted therapy · 2026Article
130 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 8 institutions in 3 countries.
Mi DengDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Xun GuiTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Jaehyup KimDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Li XieDepartment of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weina ChenDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Zunling LiDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Licai HeDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Yuanzhi ChenTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Heyu ChenDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Weiguang LuoDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Zhigang LuDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jingjing XieDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hywyn ChurchillDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Yixiang XuTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Zhan ZhouDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Guojin WuDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Chenyi YuTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Samuel JohnDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Kouyuki HirayasuDepartment of Immunochemistry, Research Institute for Microbial Diseases and Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Nam NguyenDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Xiaoye LiuDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Fangfang HuangDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Leike LiTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Hui DengTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Haidong TangDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ali H SadekDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Lingbo ZhangDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Tao HuangImmune-Onc Therapeutics, Inc., Palo Alto, CA, USA.
Yizhou ZouDepartment of Immunology, Xiangya Medical School, Central South University, Changsha, China.
Benjamin ChenDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hong ZhuDepartment of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hisashi AraseDepartment of Immunochemistry, Research Institute for Microbial Diseases and Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Ningshao XiaSchool of Public Health, Xiamen University, Xiamen, China.
Youxing JiangDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Robert CollinsDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
M James YouDepartment of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jade HomsiDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Nisha UnniDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Cheryl LewisHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Guo-Qiang ChenDepartment of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yang-Xin FuDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
X Charlene LiaoImmune-Onc Therapeutics, Inc., Palo Alto, CA, USA.
Zhiqiang AnTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA. zhiqiang.an@uth.tmc.edu.
Junke ZhengDepartment of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhengjunke@sjtu.edu.cn.
Ningyan ZhangTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA. ningyan.zhang@uth.tmc.edu.
Cheng Cheng ZhangDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. alec.zhang@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USBrown Foundation · USShanghai Jiao Tong University · CNCentral South University · CNOsaka International University · JPBinzhou University · CNThe University of Texas MD Anderson Cancer Center · USXiamen University · CN
Funding
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7MANTECEDANTS SEQUELAE OF CHILDHOOD ONSET DISEASEK12HD068369 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI SKAPEK, STEPHEN X · 2011 to 2020
$3.0MThe role of inhibitory receptors in leukemia developmentR01CA172268 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ZHANG, CHENGCHENG · 2013 to 2017
$1.6MNCI NIH HHS P30 CA142543NCI NIH HHS R01 CA172268NICHD NIH HHS K12 HD068369
Abstract
Immune checkpoint blockade therapy has been successful in treating some types of cancer but has not shown clinical benefits for treating leukaemia
Indexed as
Signal TransductionAnimalsApolipoproteins EArginaseCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell MovementCell ProliferationFemaleHumansImmune ToleranceLeukemia, Myeloid, AcuteMaleMembrane GlycoproteinsMiceMice, Inbred C57BLApolipoproteins EARG1 protein, humanArginaseLILRB4 protein, humanMembrane GlycoproteinsProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humanReceptors, Cell SurfaceReceptors, ImmunologicReceptors, Urokinase Plasminogen Activator
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.